https://mb.cision.com/Public/18595/3729972/8531f186e443fa51_800x800ar.png
** Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance=
Oncology Antibody Candidates
------------------------------------------------------------
Brussels (Belgium), and London (UK) 9 March 2023 - Cancer Research UK, the =
world=E2=80=99s largest charitable funder of cancer research, and UCB (EURO=
NEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a =
clinical development collaboration to advance two of UCB=E2=80=99s investig=
ational oncology antibody candidates through clinical trials.
The collaboration focuses on the development of two investigational antibod=
y candidates, UCB6114 and UCB4594 by bringing together the oncology-focused=
translational research and clinical development capabilities of Cancer Res=
earch UK, and UCB=E2=80=99s renowned antibody discovery expertise. If succe=
ssful in clinical trials the investigational candidates may have the potent=
ial to offer cancer patients access to new targeted treatment options. UCB6=
114 is a potential first-in-class antibody targeting gremlin-1, a glycoprot=
ein secreted by the tumour stroma^1*. UCB4594 is an antibody targeting the =
immune checkpoint, human leukocyte antigen G, also known as HLA-G.=C2=A0
Under the terms of the collaboration, Cancer Research UK=E2=80=99s Centre f=
or Drug Development will appoint the chief clinical and scientific investig=
ators, and will lead the design, preparation, sponsorship and delivery of P=
hase 1/2 clinical trials for both UCB antibody candidates. =C2=A0UCB will c=
ontinue to manufacture both investigational antibody candidates, complete t=
he ongoing UCB6114 clinical study (ONC001) and perform other supporting act=
ivities. UCB will retain exclusive rights to further develop and commercial=
ise both assets and will receive a licence to the results of the clinical t=
rials from Cancer Research UK in return for undisclosed success-based miles=
tone and royalty payments.
Dr Nigel Blackburn, Director Cancer Research UK=E2=80=99s Centre for Drug D=
evelopment, said:=C2=A0
=E2=80=9CAs funders of much of the world-class cancer research and innovati=
on happening in the UK, we are able to offer our unparalleled access to som=
e of the best oncology expertise and clinical development capabilities to o=
ur commercial partners.=E2=80=9D
=E2=80=9CWe are delighted to be collaborating with UCB to progress not one,=
but two novel oncology antibodies and here at the Centre for Drug Developm=
ent we are looking forward to progressing these programmes through early cl=
inical development.=E2=80=9D
Dhaval Patel, chief scientific officer of UCB, said:
=E2=80=9CUCB=E2=80=99s strong research productivity together with our antib=
ody expertise and desire to better understand and target the drivers of dis=
ease, has resulted in two novel and potentially disruptive candidates in on=
cology.=E2=80=9D =C2=A0
=E2=80=9CAs these candidates move forward, we are happy to enter this colla=
boration with Cancer Research UK where they will bring world leading oncolo=
gy expertise and access to a large network of clinical oncologists who can =
enable the clinical trials.=E2=80=9D
Financial details of the partnership were not disclosed.
Notes to editor:
* The tumour stroma is composed of extracellular matrix and specialized con=
nective tissue cells, including fibroblasts and mesenchymal stromal cells^2=
.
References
1. Sarker D, Banerji U, Blagden SP, et al. A multi-modular phase I/II study=
of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal =
antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/t=
ipiracil, for patients with advanced gastrointestinal (GI) tumors. J Clin O=
ncol. 2022;40(4):Suppl.TPS221.
2. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to im=
prove cancer therapy. Nat Rev Clin Oncol. 2018;15:366-381.
For media enquiries contact=C2=A0
Ellie Bennett in the Cancer Research UK press office on 020 3469 5370 or, o=
ut of hours, on 07884 466 868.
Antje Witte Investor Relations (UCB) on +32.2.559.94.14 or email antje.witt=
e@ucb.com=C2=A0
Laurent Schots, Corporate Communications (UCB) on +32.2.559.92.64 or email =
laurent.schots@ucb.com
Scott Fleming, R&D Communications (UCB) on +447702777378 or email scott.fle=
ming@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 700 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB).=C2=
=A0
About Cancer Research UK=E2=80=99s Centre for Drug Development =C2=A0
Cancer Research UK has an impressive record of developing novel treatments =
for cancer. The Cancer Research UK Centre for Drug Development has been pio=
neering the development of new cancer treatments for 25 years, taking over =
140 potential new anti-cancer agents into clinical trials in patients. It c=
urrently has a portfolio of 21 new anti-cancer agents in preclinical develo=
pment, Phase I or early Phase II clinical trials. Six of these new agents h=
ave made it to market including temozolomide for brain cancer, abiraterone =
for prostate cancer and rucaparib for ovarian cancer. Two other drugs are i=
n late development Phase III trials.=C2=A0
Forward looking statements - UCB
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
=C2=A0
GenericFile
UCB PR CRUK March 9 ENG (https://mb.cision.com/Public/18595/3729972/940ceae=
fd44d1d0f.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x130790x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01